Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles

Biomaterials

Volumn 35, Issue 11, 2014, Pages 3688-3696

  Klapper, Yvonne ^a,b,c   Hamad, Osama A ^c   Teramura, Yuji ^c,d   Leneweit, Gero ^b   Nienhaus, G Ulrich ^a,e,f   Ricklin, Daniel ^g   Lambris, John D ^g   Ekdahl, Kristina N ^c,h   Nilsson, Bo ^c  

^a KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^b Association for the Promotion of Cancer Therapy   (Germany)

^c UPPSALA UNIVERSITY   (Sweden)

^d UNIVERSITY OF TOKYO   (Japan)

^e University of Illinois at Urbana Champaign   (United States)

^f KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h LINNAEUS UNIVERSITY   (Sweden)

Author keywords

Complement; Contact activation; Immune response; Liposome

Indexed keywords

COMPLEMENT; CONTACT ACTIVATION; IMMUNE RESPONSE; LIPOSOME;

ADSORPTION; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPUTER SYSTEMS; DIMYRISTOYLPHOSPHATIDYLCHOLINE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLOW CYTOMETRY; HUMANS; LIPOSOMES; MODELS, BIOLOGICAL; PHAGOCYTOSIS; PHOSPHOLIPIDS; PROTEIN BINDING; PROTEOLYSIS; QUARTZ CRYSTAL MICROBALANCE TECHNIQUES;

EID: 84894908259     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.12.085     Document Type: Article

References (55)

1. Ulrich A.S. Biophysical aspects of using liposomes as delivery vehicles. Biosci Rep 2002, 22:129-150.
2. Szebeni J., Muggia F., Gabizon A., Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev 2011, 63:1020-1030.
3. Spector A.A., Yorek M.A. Membrane lipid composition and cellular function. J Liposome Res 1985, 26:1015-1035.
4. Chonn A., Cullis P.R., Devine D.V. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J Immunol 1991, 146:4234-4241.
5. Baron L.G., Meyer K.B., Szoka J.F.C. Effects of complement depletion on the pharmacokinetics and gene delivery mediated by cationic lipid-DNA complexes. Hum Gene Ther 1998, 9:315-323.
6. Szebeni J., Moghimi S. Liposome triggering of innate immune response: a perspective on benefits and adverse reactions. J Liposome Res 2009, 19:85-90.
7. Ishida T., Harashima H., Kiwada H. Liposome clearance. Biosci Rep 2002, 22:197-224.
8. Ekdahl K.N., Nilsson B., Pekna M., Nilsson U.R. Generation of iC3 at the interface between blood and gas. Scand J Immunol 1992, 35:85-91.
9. Janssen B.J.C., Huizinga E.G., Raaijmakers H.C.A., Roos A., Daha M.R., Ekdahl K.N., et al. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 2005, 437:505-511.
10. Ross G.D., Sl Newman, Lambris J.D., Devery-Pocius J.E., Cain J.A., Lachmann P.J. Generation of three different fragments of bound C3 with purified factor I or serum. J Exp Med 1983, 158:334-352.
11. Hugli T.E. Human anaphylatoxin (C3a) from the third component of complement. J Biol Chem 1975, 250:8293-8301.
12. Sim R.B., Twose T.M., Paterson D.S., Sim E. The covalent-binding reaction of complement component C3. Biochem J 1981, 193:115-127.
13. Pangburn M.K., Müller-Eberhardt H.J. Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3. Ann N Y Acad Sci 1983, 421:291-298.
14. Pangburn M.K., Müller-Eberhardt H.J. Relation of a putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med 1980, 152:1102-1114.
15. Law S., Dodds A.W. The internal thioester and the covalent binding properties of the complement proteins C3 and C4. Protein Sci 1997, 6:263-274.
16. Pangburn M.K., Schreiber R.D., Müller-Eberhardt H.J. Formation of the initial C3 convertase of the alternative complement pathway. J Exp Med 1981, 154:856-867.
17. Schwendinger M.G., Spruth M., Schoch J., Dierich M.P., Prodinger W.M. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells. J Immunol 1997, 158:5455-5463.
18. Alaei S., Larcher C., Ebenbichler C., Prodinger W.M., Janatova J., Dierich M.P. Isolation and biochemical characterization of the iC3b receptor of Candida albicans. Infect Immun 1993, 61:1395-1399.
19. Moghimi S., Hamad I. Liposome-mediated triggering of complement cascade. J Liposome Res 2008, 18:195-209.
20. Ishida T., Kojima H., Harashima H., Kiwada H. Biodistribution of liposomes and C3 fragments associated with liposomes evaluation of their relationship. Int J Pharm 2000, 205:183-193.
21. Devine D.V., Wong K., Serrano K., Chonn A., Cullis P.R. Liposome-complement interactions in rat serum: implications for liposome survival studies. Biochim Biophys Acta 1994, 1191:43-51.
22. Alving C.R., Richards R.L., Guirguis A.A. Cholesterol-dependent human complement activation resulting in damage to liposomal model membranes. J Immunol 1977, 118:342-347.
23. Liu D., Hu Q., Song Y.K. Liposome clearance from blood: different animal species have different mechanisms. Biochim Biophys Acta 1995, 1240:277-284.
24. Harashima H., Sakata K., Funato K., Kiwada H. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm Res 1994, 11:402-406.
25. Pham C.T.N., Mitchell L.M., Huang J.L., Lubniewskie C.M., Schall O.F., Killgore J.K., et al. Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces. J Biol Chem 2011, 286:123-130.
26. Szebeni J., Alving C.R. Complement-mediated acute effects of liposome-encapsulated hemoglobin. Artif Cells Blood Substit Immobil Biotechnol 1999, 27:23-41.
27. Szebeni J. Complement activation-related pseudoallergy caused by amphiphilic drug carriers: the role of lipoproteins. Curr Drug Deliv 2005, 2:443-449.
28. Scieszka J.F., Maggiora L.L., Wright S.D., Cho J. Role of complements C3 and C5 in the phagocytosis of liposomes by human neutrophils. Pharm Res 1997, 8:65-69.
29. Hammer C.H., Wirtz G.H., Renfer L., Gresham H.D., Tack B.F. Large scale isolation of functionally active components of the human complement system. J Biol Chem 1981, 256:3995-4006.
30. Nilsson U.R., Müller-Eberhardt H.J. Isolation of beta If-globulin from human serum and its characterization as the fifth component of complement. J Exp Med 1965, 122:277-298.
31. Fearon D.T. Purification of C3b inactivator and demonstration of its two polypeptide chain structure 1977, 119:1248-1252.
32. Nilsson B., Svensson K.E., Borwell P., Nilsson U.R. Production of mouse monoclonal antibodies that detect distinct neoantigenic epitopes on bound C3b and iC3b but not on the corresponding soluble fragments. Mol Immunol 1987, 24:487-494.
33. Bexborn F., Engberg A.E., Sandholm K., Mollnes T.E., Hong J., Ekdahl K.N. Hirudin versus heparin for use in whole blood in vitro biocompatibility models. J Biomed Mater Res A 2008, 89:951-959.
34. Katragadda M., Magotti P., Sfyroera G., Lambris J. Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, Compstatin. J Med Chem 2006, 49:4616-4622.
35. Nilsson B., Svensson K.E., Inganäs M., Nilsson U.R. A simplified assay for the detection of C3a in human plasma employing a monoclonal antibody raised against denatured C3. J Immunol Methods 1988, 107:281-287.
36. Alsenz J., Becherer J.D., Nilsson B., Lambris J.D. Structural and functional analysis of C3 using monoclonal antibodies. Curr Top Microbiol 1990, 153:235-248.
37. Finch A., Wong A., Paczkowski N., Wadi S., Craik D., Fairlie D., et al. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a 1999, 42:1965-1974.
38. Sauerbrey G. Verwendung von Schwingquarzen zur Wägung dünner Schichten und zur Mikrowägung. Z Physiother 1959, 55:206-222.
39. Rodahl M., Höök F., Krozer A., Brzezinski P., Kasemo B. Quartz-crystal microbalance setup for frequency and Q-factor measurements in gaseous and liquid environments. Rev Sci Instrum 1995, 66:3924-3930.
40. Cho N.J., Curtis W.F., Kasemo B., Höök F. Quartz-crystal microbalance with dissipation monitoring of supported lipid bilayers on various substrates. Nat Protoc 2010, 5:1096-1106.
41. Ricklin D., Lambris J.D. Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol 2008, 632:273-292.
42. Ricklin D., Lambris J.D. Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol 2013, 190:3839-3847.
43. Devine D.V., Marjan J.M. The role of immunoproteins in the survival of liposomes in the circulation. Crit Rev Ther Drug Carrier Syst 1997, 14:105-131.
44. Yan X., Scherphof G., Kamps J. Liposome opsonization. J Liposome Res 2005, 15:109-139.
45. Szebeni J., Baranyi L., Savay S., Milosevits J., Bodo M., Bunger R., et al. The interaticion of liposomes with the complement system: in vitro and in vivo assays. Meth Enzymol 2003, 373:136-154.
46. Jiang H., Robey F.A., Gewurz H. Localization of sites through which C-reactive protein binds and activates complement to residues 14-26 and 76-92 of the human C1q A chain. J Exp Med 1992, 175:1373-1379.
47. Johnstone A., Masin D., Mayer L., Bally M. Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. Biochim Biophys Acta 2001, 1513:25-37.
48. Price M., Cornelius R., Brash J. Protein adsorption to polyethylene glycol modified liposomes from fibrinogen solution and from plasma. Biochim Biophys Acta 2001, 1512:191-205.
49. Sabin J., Prieto G., Ruso J., Messina P., Salgado F., Nogueira M., et al. Interactions between DMPC liposomes and the serum blood proteins HSA and IgG. J Phys Chem B 2009, 113:1655-1661.
50. Malmsten M. Studies of serum protein adsorption at phospholipid surfaces in relation to intravenous drug delivery. Colloid Surf A 1999, 159:77-87.
51. Sim R., Sim E. Autolytic fragmentation of complement components C3 and C4 under denaturing conditions, a property shared with α2-macroglobulin. Biochem J 1981, 93:129-141.
52. Andersson J., Ekdahl K.N., Lambris J.D., Nilsson B. Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surface. Biomaterials 2005, 26:1477-1485.
53. Hamad O.A., Nilsson P.H., Wouters D., Lambris J.D., Ekdahl K.N., Nilsson B. Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1. J Immunol 2010, 184:2686-2692.
54. Pekna M., Nilsson L., Ekdahl K.N., Nilsson U.R., Nilsson B. Evidence for iC3 generation during cardiopulmonary bypass as the result of blood-gas interaction. Clin Exp Immunol 1993, 91:404-409.
55. Nilsson U.R., Storm K., Elwing H., Nilsson B. Conformational epitopes of C3 reflecting its mode of binding to an artificial polymer surface. Mol Immunol 1993, 30:211-219.